กำลังโหลด
HKSEHealthcareDrug Manufacturers - Specialty & Generic
ข้อมูลล่าสุด
HK$3.925
+HK$0.075 · +1.95%
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
ข้อมูลล่าสุด
HK$3.925
+HK$0.075 · +1.95%
เวลาในวันใช้เขตเวลาHKT ข้อมูลตลาดอาจล่าช้า
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
ช่วงราคารายวัน
ปัจจุบัน HK$3.925
ช่วง 52 สัปดาห์
ปัจจุบัน HK$3.925
เวลาในวันใช้เขตเวลาHKT ข้อมูลตลาดอาจล่าช้า
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
ช่วงราคารายวัน
ปัจจุบัน HK$3.925
ช่วง 52 สัปดาห์
ปัจจุบัน HK$3.925
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (CNY) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 5.48B CNY | 5.28B CNY | 5.45B CNY | 7.16B CNY | 6.37B CNY |
| ต้นทุนสินค้าขาย | 3.74B CNY | 3.52B CNY | 3.65B CNY | 4.83B CNY | 4.33B CNY |
| กำไรขั้นต้น | 1.74B CNY | 1.76B CNY | 1.8B CNY | 2.33B CNY | 2.03B CNY |
| การวิจัยและพัฒนา | 226.16M CNY | 212.04M CNY | 184.66M CNY | 252.14M CNY | 221.1M CNY |
| การขาย ทั่วไป และธุรการ | 478.17M CNY | 454.67M CNY | 590.13M CNY | 665M CNY | 572.83M CNY |
| ค่าใช้จ่ายในการดำเนินงาน | 1.11B CNY | 1.01B CNY | 2.66B CNY | 1.21B CNY | 1.07B CNY |
| รายได้ดอกเบี้ย | 38.27M CNY | 44.37M CNY | 39.52M CNY | 54.14M CNY | 54.86M CNY |
| ดอกเบี้ยจ่าย | 71.44M CNY | 141.18M CNY | 223.22M CNY | 235.24M CNY | 201.63M CNY |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 372.91M CNY | 331.05M CNY | 373.6M CNY | 307.66M CNY | 302.74M CNY |
| รายได้จากการดำเนินงาน | 635.97M CNY | 741.31M CNY | −238.11M CNY | 1.14B CNY | 773.2M CNY |
| รายได้สุทธิ | 349.49M CNY | 646.74M CNY | −783.26M CNY | 727.43M CNY | 240.79M CNY |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 9 ต.ค. 2569.
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
Dimensional - Emerging Markets Core Equity 2 ETFDFEM109.37K0.00%9.73B USD0.39%US$39.58-1.54%
Dimensional - Emerging Core Equity Market ETFDFAE74.86K0.00%10.2B USD0.29%US$39.02-1.69%
Dimensional World ex U.S. Core Equity 2 ETFDFAX45.94K0.00%12.37B USD0.28%US$36.80-0.76%
Dimensional - Emerging Markets Value ETFDFEV36.7K0.00%2.2B USD0.46%US$42.16-1.47%
Vanguard Total International Stock ETFVXUS11K—665.7B USD0.05%US$84.10-0.81%
Vanguard Total World Stock ETFVT8.53K0.00%101.7B USD0.06%US$158.73-0.57%Dimensional - Emerging Markets Core Equity 2 ETFDFEMDimensional - Emerging Core Equity Market ETFDFAEDimensional World ex U.S. Core Equity 2 ETFDFAXDimensional - Emerging Markets Value ETFDFEVVanguard Total International Stock ETFVXUSVanguard Total World Stock ETFVTเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน